Literature DB >> 23575413

Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients.

Chong-Kin Liam1, Mohamed Ibrahim A Wahid, Pathmanathan Rajadurai, Yoke-Kqueen Cheah, Tiffany Shi-Yeen Ng.   

Abstract

INTRODUCTION: Despite available data from other Asian countries, the prevalence of epidermal growth factor receptor (EGFR) mutations among lung adenocarcinoma patients has not been reported in Malaysia. This study sought to determine the frequency of EGFR mutations among multiethnic Malaysian patients diagnosed with lung adenocarcinoma.
METHODS: Demographic and clinical information of patients whose lung adenocarcinoma biopsy specimens were submitted for EGFR mutation testing at Sime Darby Medical Center from 2009 to 2011 were analyzed. EGFR mutations at exons 18, 19, 20, and 21 were detected either through bidirectional sequencing or real-time polymerase chain reaction.
RESULTS: Among 812 patients in the study, 49% were female, 63.7% were ethnic Chinese, 29.4% Malay, 4.8% Indian, and 2.1% other ethnic groups. Mutations were present in the tumors of 321 patients (39.5%), with mutations at exons 19 (23.5%) and 21 (14.9%) being the most common. Mutations were significantly more frequent among women than in men (52.5% versus 27.8%, p < 0.001). Although mutations were more common among Chinese (40.8%) compared with Malay (37.2%) or Indian (33.3%) patients, the difference was not statistically significant (p = 0.591). Of 211 patients with smoking history records, never-smokers had a higher mutation rate compared with ever-smokers (54.8% versus 20.7%, p < 0.001).
CONCLUSION: EGFR mutations were present in 39.5% of patients. Mutations were more common in women and never-smokers with no differences in mutation frequency between different ethnicities. Because of the high mutation rates, reflex testing for EGFR mutation should be a routine practice for advanced lung adenocarcinoma patients in Malaysia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23575413     DOI: 10.1097/JTO.0b013e31828b5228

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  16 in total

1.  The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.

Authors:  Yoshikazu Hasegawa; Masahiko Ando; Makoto Maemondo; Satomi Yamamoto; Shun-Ichi Isa; Hideo Saka; Akihito Kubo; Tomoya Kawaguchi; Minoru Takada; Rafael Rosell; Takayasu Kurata; Sai-Hong Ignatius Ou
Journal:  Oncologist       Date:  2015-02-05

2.  Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis.

Authors:  Li Lv; Zhichao Liu; Yang Liu; Wenhui Zhang; Lifeng Jiang; Tingting Li; Xinyan Lu; Xuefen Lei; Wenhua Liang; Jie Lin
Journal:  Front Oncol       Date:  2020-11-02       Impact factor: 6.244

3.  Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.

Authors:  Yuhui Ma; Quan Li; Yaxi Du; Wanlin Chen; Guanqiang Zhao; Xing Liu; Hongsheng Li; Junxi Liu; Zhenghai Shen; Luyao Ma; Yongchun Zhou
Journal:  Cancer Manag Res       Date:  2020-10-29       Impact factor: 3.989

4.  Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.

Authors:  Yulong Zheng; Weijia Fang; Jing Deng; Peng Zhao; Nong Xu; Jianying Zhou
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

5.  Targeted Therapy Management in NSCLC Patients Using Cytology: Experience from a Tertiary Care Cancer Center.

Authors:  Vidya H Veldore; Shekar Patil; Shilpa Prabhudesai; C T Satheesh; H P Shashidhara; Naveen Krishnamoorthy; D Hazarika; R Tejaswi; Ankita Prabhudev; Radheshyam Naik; Raghavendra M Rao; B S Ajai Kumar
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

6.  The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC).

Authors:  Hanan H Ramadhan; Dhuha F Taaban; Jubran K Hassan
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

7.  Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.

Authors:  Yongchun Zhou; Yanlong Yang; Chenggang Yang; Yunlan Chen; Changshao Yang; Yaxi Du; Guangqiang Zhao; Yinjin Guo; Lianhua Ye; Yunchao Huang
Journal:  Oncotarget       Date:  2017-02-28

8.  Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.

Authors:  Sung-Jun Ko; Yeon Joo Lee; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Jin-Haeng Chung; Tae Jung Kim; Kyung Won Lee; Kwhanmien Kim; Sanghoon Jheon; Hyojin Kim; Jae Ho Lee; Choon-Taek Lee
Journal:  BMC Cancer       Date:  2014-05-03       Impact factor: 4.430

9.  In Silico Screening of Mutated K-Ras Inhibitors from Malaysian Typhonium flagelliforme for Non-Small Cell Lung Cancer.

Authors:  Ayesha Fatima; H F Yee
Journal:  Adv Bioinformatics       Date:  2014-09-21

10.  Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.

Authors:  Yongchun Zhou; Yuhui Ma; Hutao Shi; Yaxi Du; Yunchao Huang
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.